Low-Dose X-ray Excited Photodynamic Therapy Based on NaLuF4:Tb3+–Rose Bengal Nanocomposite

Xiaofeng Zhang,Bin Lan,Sicheng Wang,Peng Gao,Tianshuai Liu,Junyan Rong,Feng Xiao,Lichun Wei,Huanyu Lu,Cui Pang,Li Fan,Wenli Zhang,Hongbing Lu
DOI: https://doi.org/10.1021/acs.bioconjchem.9b00429
IF: 4.7
2019-01-01
Bioconjugate Chemistry
Abstract:X-ray excited photodynamic therapy (X-PDT), which utilizes X-rays as the energy source and X-ray luminescent nanoparticles (XLNPs) as the transducer to excite photosensitizers (PS), resolves the penetration problem of light in traditional PDT to enable the treatment of deep-seated tumors. Nevertheless, the high X-ray dosage used in X-PDT hampers its potential applications in clinics. In this study, to alleviate the dose problem, β-NaLuF4:Tb3+ spherical nanoparticles (NPs) with ultrastrong green X-ray excited optical luminescence (XEOL) due to the less nonradiative relaxation probability and high X-ray absorption mass coefficient, which perfectly matches the absorption spectrum of a photosensitizer named rose bengal (RB), were synthesized and employed as the energy transducer for X-PDT. After covalent conjugation of NPs with RB, high Förster resonant energy transfer (FRET) efficiency up to 94.29% was achieved, leading to high production of singlet oxygen. In vivo X-PDT efficacy was evaluated by nude mice with a HepG2 tumor xenograft. With excellent biocompatibility, the synthesized NPs–RB nanocomposite showed significant antitumor efficiency up to 80 ± 12.3% with a total X-ray dose of only 0.19 Gy, demonstrating the feasibility of low-dose X-PDT in vivo for the first time. The present work provides a promising platform for X-PDT in deep-seated tumors.
What problem does this paper attempt to address?